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Objectives The goal of this study was to identify potentially novel laboratory markers of risk in chronic heart failure
patients.
Background Although a variety of prognostic markers have been described in heart failure, a systematic assessment of rou-
tine laboratory values has not been reported.
Methods All 2,679 symptomatic chronic heart failure patients from the North American CHARM (Candesartan in Heart
Failure: Assessment of Reduction in Mortality and Morbidity) program had a wide range of laboratory measures
performed at a core facility, enabling us to assess the relationship between routine blood tests and outcomes
using a Cox proportional hazards model. We then replicated our findings in a cohort of 2,140 heart failure pa-
tients from the Duke Databank.
Results Among 36 laboratory values considered in the CHARM program, higher red cell distribution width (RDW) showed
the greatest association with morbidity and mortality (adjusted hazard ratio 1.17 per 1-SD increase, p  0.001).
Higher RDW was among the most powerful overall predictors, with only age and cardiomegaly showing a better
independent association with outcome. This finding was replicated in the Duke Databank, in which higher RDW
was strongly associated with all-cause mortality (adjusted hazard ratio 1.29 per 1 SD, p  0.001), second only
to age as a predictor of outcome.
Conclusions In 2 large contemporary heart failure populations, RDW was found to be a very strong independent predictor of
morbidity and mortality. Understanding how and why this marker is associated with outcome may provide novel
insights into heart failure pathophysiology. (J Am Coll Cardiol 2007;50:40–7) © 2007 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.067n
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occurate risk stratification of patients with chronic heart
ailure is critically important to efficiently target the use
f evidence-based therapies and identify high-risk pa-
ients who may benefit from advanced treatments. In
ddition to improving risk stratification, identification of
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007, accepted February 25, 2007.ew prognostic markers may provide insight into under-
ying pathophysiology or suggest avenues for therapeutic
evelopment. To date, a wide variety of clinical variables
nd biological markers have been used to create predictive
odels for survival in patients with chronic heart
ailure (1,2).
Routine measurement of panels of laboratory tests is
early ubiquitous in the management of heart failure (3).
any laboratory findings have been shown to be associated
ith outcome in heart failure (4,5). Previous analyses from
he CHARM (Candesartan in Heart Failure: Assessment of
eduction in Mortality and Morbidity) program have high-
ighted the prognostic value of anemia across a broad range
f ejection fractions in patients with chronic heart failure
6). However, the nature of interaction between the hema-
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July 3, 2007:40–7 Red Cell Distribution Width in Heart Failureological system and the heart failure syndrome remains
oorly characterized.
The CHARM program was unique among large prospec-
ive heart failure trials in that it analyzed a wide range of
aboratory values at a central core laboratory in a large cohort of
atients. Thus, the CHARM program provides a distinctive
pportunity to broadly characterize routine laboratory values in
contemporary chronic heart failure cohort and assess their
elationship to outcome. The purpose of this study was to
dentify and validate new prognostic markers for chronic heart
ailure among 36 commonly collected laboratory measures.
First, we analyzed data from the CHARM program to
dentify laboratory parameters that were associated with clinical
utcomes (derivation phase). Subsequently, we sought to
eplicate our findings in an independent dataset, the Duke
atabank for Cardiovascular Disease. We herein report the
Baseline Characteristics for CHARM North Ame
Table 1 Baseline Characteristics for CHARM
Variable
With
Mea
Demographic and clinical
Age (yrs) 6
Ejection fraction
Heart rate (beats/min) 7
Systolic blood pressure (mm Hg) 12
Diastolic blood pressure (mm Hg) 7
Body mass index (kg/m2) 2
Female 3
NYHA functional class II 4
NYHA functional class III 5
NYHA functional class IV
Race (white) 8
Previous hospitalization for HF 6
Etiology (ischemic) 6
Medical history
Previous MI 5
Stroke
Hypertension 6
Diabetes mellitus 3
Coronary artery bypass grafting 3
Percutaneous coronary revascularization 2
Implanted cardioverter-defibrillator
Atrial fibrillation 2
Signs and symptoms
Dyspnea on exertion 6
Venous congestion 3
S3 gallop 1
Cardiomegaly
Pulmonary crackles 1
Electrocardiogram
Atrial fibrillation/flutter 1
Bundle branch block 1
Pathological Q-wave 1
Left ventricular hypertrophy 1CHARM  Candesartan in Heart Failure: Assessment of Reduction in Mort
myocardial infarction; NYHA  New York Heart Association.dentification and validation of red
ell distribution width (RDW) as a
ovel independent predictor of ad-
erse outcomes in patients with
hronic heart failure.
ethods
atient population for deriva-
ion dataset. Details and key
ndings of the CHARM pro-
ram have been published previously (7). Briefly, the
HARM program randomized patients with symptomatic
hronic heart failure to candesartan or placebo. The pro-
ram consisted of 3 separate trials that shared inclusion and
xclusion criteria, end point definitions, and follow-up
Study Cohort
th American Study Cohort
CV Death or HF Hospitalization
ent (n  1,727) With Event (n  952)
SD Mean or % SD
11.5 67.4 11.3
0.15 0.35 0.16
11.8 73.0 12.2
18.0 126.5 19.8
10.6 71.8 10.6
6.4 29.3 6.5
31.7%
24.5%
70.1%
5.5%
85.8%
77.7%
71.5%
57.1%
12.7%
68.2%
48.8%
34.9%
19.7%
5.1%
35.2%
76.7%
47.7%
22.1%
20.1%
16.8%
13.6%
27.5%
13.7%
14.1%
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
HR  hazard ratio
NYHA  New York Heart
Association
RDW  red cell distribution
widthrican
Nor
out Ev
n or %
4.1
0.40
1.2
9.1
4.7
9.8
4.3%
2.7%
6.1%
1.3%
4.8%
2.4%
5.0%
1.1%
9.4%
5.8%
0.8%
0.8%
0.8%
3.5%
5.3%
6.3%
6.1%
2.9%
8.4%
0.5%
0.2%
8.1%
6.3%
3.8%ality and Morbidity; CV  cardiovascular; HF  heart failure; MI 
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Red Cell Distribution Width in Heart Failure July 3, 2007:40–7ethods. The study included: 1) patients with left ventric-
lar ejection fraction 40% (CHARM-preserved); 2) pa-
ients with angiotensin-converting enzyme (ACE) inhibitor
ntolerance and a left ventricular ejection fraction 40%
CHARM-alternative); and 3) patients on ACE inhibitors
nd with a left ventricular ejection fraction 40%
CHARM-added). The primary end point of each constit-
ent trial was time to cardiovascular death or hospitalization
or the management of worsening heart failure (adjudicated
y a blinded events committee), and the primary end point
f the overall program was all-cause mortality. All patients
nrolled in the CHARM program in North America (n 
,679) had a panel of routine laboratory tests measured at
Baseline Laboratory Measures Evaluated asPot ntial Predic s in CHARM North America S
Table 2 Baseline Laboratory Measures EvalPotential Predictors in CHARM Nor
Laboratory Parameters
Without E
Mean
Biochemical
ALT(SGPT) (U/l) 21.9
AST(SGOT) (U/l) 21.6
Alkaline phosphatase (U/l) 84.6
Creatine kinase (U/l) 114.6
Creatinine (mg/dl) 1.1
Bilirubin total (mg/dl) 0.61
Bilirubin direct (mg/dl) 0.16
Sodium (mmol/l) 140.4
Potassium (mmol/l) 4.4
Calcium (mg/dl) 9.6
Chloride (mmol/l) 102.9
Phosphorus inorganic (mg/dl) 3.4
Albumin (g/dl) 4.15
Protein total (g/dl) 7.22
Glucose (mg/dl) 135
Uric acid (mg/dl) 6.7
Cholesterol (mg/dl) 197
Triglyceride (mg/dl) 230
Globulin total (g/dl) 3.08
Urea nitrogen (mg/dl) 25
Hematologic
Hematocrit (%) 41.1
Red cell count (106/l) 4.5
Hemoglobin (g/dl) 13.7
White cell count (103/mm3) 7.2
Platelet count (103/mm3) 233.1
Neutrophils segmented (%) 63.5
Eosinophils (%) 3.1
Basophils (%) 0.4
Lymphocytes (%) 26.5
Monocytes (%) 6.3
MCH (pg/cell) 30.7
MCHC (g/dl) 33.4
MCV (m3) 92.1
Glycohemoglobin A1C (%) 6.8
RDW (%) 14.4ALT(SGPT)  alanine transaminase; AST(SGOT)  aspartate transaminase;
hemoglobin concentration; MCV  mean corpuscular volume; RDW  red ce.he time of randomization by a central core laboratory, and
his cohort served as the population for this analysis.
ollow-up was for a median of 34 months in the study
ohort. The CHARM trials were approved by the institu-
ional review boards of participating centers.
tatistical methods for derivation dataset. Baseline vari-
bles were described using means and standard deviations
r percentages, as appropriate. Correlations between
ariables of interest were determined using correlation
oefficients. A Cox proportional hazards model was used
o evaluate the relationship between preselected clinical
ariables and the end point of interest. This modeling
as performed separately for time to cardiovascular death
Cohort
as
erica Study Cohort
CV Death or HF Hospitalization
n  1,727) With Event (n  952)
SD Mean SD
18.6 21.0 15.1
12.5 22.1 15.4
33.0 92.3 47.7
115.3 104.2 96.3
0.4 1.3 0.9
0.32 0.72 0.47
0.12 0.20 0.19
2.9 140.0 3.2
0.4 4.4 0.5
0.4 9.6 0.4
3.4 101.7 4.3
1.2 3.4 1.2
0.31 4.07 0.33
0.51 7.23 0.57
68.5 151 82.9
2.0 7.6 2.3
46 189 50
195 221 177
0.48 3.16 0.52
12 32 17
4.5 40.2 5.2
0.5 4.4 0.6
1.5 13.4 3.1
2.1 7.6 2.3
69.9 226.5 68.4
9.2 66.3 9.5
2.1 3.1 2.4
0.3 0.4 0.4
8.4 23.6 8.7
2.5 6.5 2.8
2.3 30.4 2.4
1.1 33.2 1.1
5.6 91.6 6.3
1.4 7.3 1.6
1.6 15.2 2.0tudy
uated
th Am
vent (MCH  mean corpuscular hemoglobin; MCHC  mean corpuscular
ll distribution width; other abbreviations as in Table 1.
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July 3, 2007:40–7 Red Cell Distribution Width in Heart Failurer heart failure hospitalization (the primary end point of
he constituent trials) and for all-cause mortality (the
rimary end point of the overall program). A “best
linical model” (excluding laboratory data) was created
rom the overall program dataset (n  7,599) using
tandard modeling techniques (2). Briefly, models were
uilt using a forward stepwise variable selection proce-
ure. A value of p  0.01 was set as the level of
ignificance for including variables in the model because
f the large number of candidate variables being consid-
red. Randomization to candesartan or placebo was
ncluded in all models. The variables selected for this
odel were then used to estimate a final model for the
tudy cohort for whom laboratory data were available (n
2,679). Subsequently, laboratory parameters were
dded to this model one at a time in a forward stepwise
ashion to generate a final model that combined both
linical and laboratory parameters. Adjusted hazard ratios
HRs) for continuous variables were described using
tandardized HRs, the HR associated with a 1-SD
hange in the variable. The statistical contribution of
ach variable to the prediction of outcome was assessed
y the chi-square statistic.
To evaluate the potential effects of non-normal distribu-
ion of laboratory values on our findings, we repeated the
odeling with log transformation on all laboratory values
efore entering them into the model. To evaluate the
ossibility of nonlinear relationships between variables and
utcome, we repeated the models with a quadratic term
Final Multivariable Model for Cardiovascular DeaHospitalization in the CHARM Coh rt (Including
Table 3 Final Multivariable Model for CardioHospitalization in the CHARM Coho
Variables Ha
Laboratory parameters
RDW
Bilirubin total
Lymphocytes
Uric acid
Glycohemoglobin A1C
Hemoglobin
Creatinine
Phosphorus inorganic
Clinical variables
Age (per 10 yrs over age 60)
Ejection fraction (per 5% decrease below 45)
Diabetes: insulin treated
Diabetes: other
Prior HF hospitalization within 6 months
Prior HF hospitalization but not within 6 months
Cardiomegaly
NYHA functional class III
NYHA functional class IV
Diagnosis of HF over 2 yrs ago
Bundle branch block
Randomization to candesartan*Hazard ratios for continuous variables shown as standardized hazard ratios
Abbreviations as in Table 1.ncluded for each laboratory value. Finally, we tested for
tatistical interactions between variables for which there was
theoretical rationale for interactions.
eplication dataset. To assess the validity of these find-
ngs, we investigated the prognostic association of labora-
ory variables identified in the CHARM program in an
ndependent cohort of patients from the Duke Databank for
ardiovascular Disease. Briefly, the Duke Databank is a
linical database that includes all patients who have under-
one cardiac catheterization at Duke University Medical
enter since 1969 (8). Mortality follow-up data are com-
lete for over 96% of patients. For the purposes of this
nalysis, we defined a dataset that would be composed of a
ontemporary, broadly representative heart failure popula-
ion similar to that in the CHARM program. This con-
isted of patients entered into the Duke Databank from
999 to 2003 who had symptomatic heart failure (New York
eart Association [NYHA] functional class II or greater)
egardless of ejection fraction, and who had an RDW value
vailable. Patients were excluded from the analysis if they
ad primary valvular heart disease or complex congenital
eart disease. Because data on cause of subsequent hospi-
alizations and cause of death were not universally available,
ime to all-cause mortality was used as the primary end
oint for the replication phase. The replication study was
pproved by the Duke University Institutional Review
oard.
In the replication dataset, multivariable Cox proportional
azards modeling was used to identify the relationship
r Heart Failureratory and Clinical Variables)
ular Death or Heart Failure
cluding Laboratory and Clinical Variables)
atio* 95% CI Chi-Square p Value
7 1.10–1.25 24.78 0.0001
4 1.08–1.21 20.72 0.0001
6 0.80–0.93 15.09 0.0001
3 1.06–1.21 12.20 0.0005
2 1.04–1.22 8.46 0.004
0 0.84–0.97 8.15 0.004
3 1.03–1.23 6.79 0.009
8 1.01–1.16 5.45 0.02
2 1.21–1.44 41.32 0.0001
9 1.29–1.97 18.24 0.0001
1 1.10–1.56 8.84 0.003
7 1.04–1.11 17.62 0.0001
3 1.28–1.84 21.11 0.0001
7 0.98–1.40 3.19 0.074
6 1.33–1.84 28.15 0.0001
2 1.21–1.66 18.88 0.0001
9 1.52–2.89 20.43 0.0001
6 1.17–1.57 16.62 0.0001
4 1.07–1.44 8.34 0.004
9 0.69–0.90 12.59 0.0004th oLabo
vasc
rt (In
zard R
1.1
1.1
0.8
1.1
1.1
0.9
1.1
1.0
1.3
1.5
1.3
1.0
1.5
1.1
1.5
1.4
2.0
1.3
1.2
0.7(HR per 1 SD).
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Red Cell Distribution Width in Heart Failure July 3, 2007:40–7etween RDW and all-cause mortality after adjustment for
ther clinical and laboratory predictors of outcome. As in
he CHARM database, the relationship between RDW and
utcome was expressed as a standardized HR.
esults
he CHARM population characteristics. Baseline clin-
cal characteristics for patients enrolled in the CHARM
rogram in North America (n  2,679) are shown in
able 1. Thirty-six laboratory parameters obtained as
art of standard chemistry and hematology panels were
onsidered as potential laboratory predictors of outcome
listed in Table 2).
aboratory predictors of outcome in the CHARM pro-
ram. In the CHARM cohort, 952 patients suffered a
rimary outcome event (cardiovascular death or heart failure
ospitalization). As previously described, a best clinical
odel was initially constructed using clinical characteristics
lone (without laboratory values or medications). In this
linical model, the most powerful predictors of outcome
ere diabetes mellitus, recent hospitalization for heart
ailure, age, and ejection fraction (2). The 36 candidate
aboratory parameters were then evaluated to identify asso-
iations between each individual biochemical variable and
utcome. In univariable analysis of laboratory predictors
adjusted for the variables in the final clinical model but not
or other laboratory variables), the most powerful (based on
he chi-square statistic) laboratory predictors of outcome
ere increased RDW, increased uric acid, and increased
lood urea nitrogen. To evaluate these laboratory parame-
ers in the context of all available clinical information, a final
ultivariable model was generated that included all signif-
cant laboratory and clinical predictors (Table 3). In this
nal model, the laboratory values most predictive of adverse
utcomes were increased RDW (HR 1.17 per 1-SD in-
rease, p  0.0001), higher total bilirubin (HR 1.14 per
-SD increase, p  0.0001), decreased lymphocyte count
HR  0.86 per 1-SD increase, p  0.0001), and increased
ric acid (HR 1.13 per 1-SD increase, p 0.0005). Notably
n this final model, increased RDW was among the most
ignificant overall predictors of outcome, showing stronger
tatistical association than many traditional measures of risk
uch as NYHA functional class and ejection fraction. Of
linical variables tested, only age and cardiomegaly showed
tronger independent association with outcome than RDW.
og-transforming laboratory values did not significantly
lter the association of RDW with outcomes (HR  1.85
or 1-SD increase in the log of RDW, p 0.0001), nor was
here any evidence for a nonlinear relationship between
DW and outcome (p value for quadratic term of RDW 
.11). The relationship of RDW to the primary composite
utcome is shown in Figure 1A. The effect of candesartan in
educing the primary composite outcome in the CHARM
rogram (Table 3) was not modified by the baseline level of
DW. jTo further evaluate this association, we repeated the
odeling using the end point of all-cause mortality (625
vents). In this mortality analysis, the association between
DW and outcome was less marked, but RDW remained a
ighly significant independent predictor of outcome (ad-
Figure 1 Outcomes by RDW Quintiles
Adjusted hazard ratios by quintile of red cell distribution width (RDW) for cardio-
vascular (CV) death or heart failure (HF) hospitalization in the CHARM (Cande-
sartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity)
program (A), all-cause mortality in CHARM (B), and all-cause mortality in Duke
Databank (C).usted HR 1.12 per 1-SD increase, p  0.006) after
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July 3, 2007:40–7 Red Cell Distribution Width in Heart Failuredjustment for other clinical and laboratory measures (Fig.
B, Table 4).
eplication in Duke Databank. The replication dataset
ontained 2,140 patients from the Duke Databank who
xperienced 368 end points (deaths). In univariate analysis,
e found RDW to be strongly predictive of all-cause
ortality (HR 1.47 per 1-SD increase, p  0.001). After
djustment for a wide range of clinical and laboratory
ovariates in a multivariable model, RDW remained
trongly associated with mortality (adjusted HR 1.29 per
-SD increase, p  0.001) (Table 5, Fig. 1C). Based on
hi-square analysis, RDW was second only to age with
Final Multivariable Model for All-Cause Mortalityin CHARM Cohort (Including Laboratory and Clin
Table 4 Final Multivariable Model for All-Cain CHARM Cohort (Including Labora
Variable
Laboratory parameters
Chloride
Bilirubin total
Urea nitrogen
Albumin
Hemoglobin
Sodium
RDW
Monocytes
Cholesterol
Clinical variables
Age (per 10 yrs over age 60)
Ejection fraction (per 5% decrease below 45)
Female
Diagnosis of HF over 2 yrs ago
Current smoker
Diabetes: insulin treated
Diabetes: other
Dependent edema
Body mass index (per 1 kg/m2 decrease below 27.5)
NYHA functional class III
Bundle branch block
NYHA functional class IV
Diastolic blood pressure (per 10-mm Hg decrease)
*Hazard ratios for continuous variables shown as standardized hazard
Abbreviations as in Table 1.
Final Multivariable Analysis for All-Cause Mortal
Table 5 Final Multivariable Analysis for All-C
Variable Hazard Ratio*
Age 1.49
RDW 1.29
Hemoglobin 0.79
Number of diseased vessels 1.19
Noncardiac Charlson index† 1.14
Systolic blood pressure 0.85
Ejection fraction 0.88
History of hypertension 0.78
Male 1.27
*Hazard ratios for continuous variables shown as standardized hazard
comorbidity.
Abbreviations as in Table 1.egard to the statistical strength of association as a predictor
f all-cause mortality.
DW and hemoglobin. Given the association of hemo-
lobin with adverse outcomes seen in previous studies, we
valuated the relationship between hemoglobin and RDW
n both the CHARM dataset and the Duke Databank. In
oth datasets, RDW and hemoglobin were moderately
egatively correlated with each other (correlation coefficient
f 0.27 in the CHARM program and 0.40 in the Duke
atabank). In all final multivariable models, both RDW
nd hemoglobin were significant predictors even after adjust-
ent for all other predictors. There was no evidence for
Variables)
ortality
and Clinical Variables)
rd Ratio* 95% CI Chi-Square p Value
0.78 0.71–0.85 31.80 0.0001
1.19 1.11–1.27 24.08 0.0001
1.18 1.10–1.26 20.20 0.0001
0.85 0.78–0.93 14.24 0.0002
0.84 0.76–0.92 13.75 0.0002
1.14 1.04–1.25 8.18 0.004
1.12 1.03–1.20 7.65 0.006
1.11 1.02–1.20 6.63 0.0100
1.10 1.01–1.20 4.87 0.03
1.49 1.33–1.66 49.20 0.0001
1.13 1.09–1.18 35.11 0.0001
0.63 0.52–0.76 21.70 0.0001
1.48 1.24–1.76 18.70 0.0001
1.69 1.32–2.15 17.77 0.0001
1.60 1.26–2.03 14.72 0.0001
1.41 1.16–1.71 12.09 0.0005
1.34 1.13–1.60 10.85 0.001
1.05 1.02–1.09 8.79 0.003
1.33 1.10–1.62 8.40 0.004
1.29 1.08–1.54 7.87 0.005
1.68 1.14–2.48 6.77 0.009
1.09 1.01–1.19 4.84 0.03
(HR per 1 SD).
om Duke Databank Cohort
Mortality From Duke Databank Cohort
95% CI Chi-Square p Value
1.32–1.69 39.17 0.0001
1.16–1.43 21.65 0.0001
0.71–0.88 17.74 0.0001
1.08–1.30 13.31 0.0003
1.05–1.23 11.02 0.0009
0.76–0.95 8.75 0.003
0.78–0.98 5.30 0.02
0.62–0.99 4.33 0.04
1.01–1.60 4.10 0.04
HR per 1 SD). †Charlson index is a combined measure of noncardiacical
use M
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Red Cell Distribution Width in Heart Failure July 3, 2007:40–7tatistical interaction between RDW and hemoglobin (p 
.05 for interaction term in all models). The RDW was a more
owerful predictor (based on chi-square analysis) than hemo-
lobin in the CHARM composite end point model and the
uke Databank mortality model. Hemoglobin was a stronger
redictor than RDW in the CHARM mortality model.
iscussion
he primary finding of this study is that increased RDW
as a strong independent predictor of greater morbidity and
ortality in patients with chronic heart failure. This finding
as observed in a large clinical trial database and subse-
uently replicated in a large hospital registry database. This
ssociation remained after adjustment for a wide variety of
linical and laboratory variables. In both datasets RDW was
mong the strongest prognostic markers. The RDW had
igher statistical association with outcome than widely
ccepted measures of risk such as ejection fraction, NYHA
unctional class, and renal function. To our knowledge, this
epresents the first report of elevated RDW as a potential
rognostic marker in chronic heart failure.
Several features support the validity of our findings. The
ther prognostic markers identified in our analyses are
onsistent with previously published models in heart failure,
ith regard to both traditional markers of risk (such as age,
jection fraction, and NYHA functional class) and other
rognostic laboratory markers (9,10). The confirmation of
ur observation in an independent dataset suggests that the
ssociation between RDW and outcome is very unlikely to
e caused by the play of chance.
otential mechanisms. Red cell distribution width is a
uantitative measure of anisocytosis, the variability in size of
he circulating erythrocytes. It is routinely measured by
utomated hematology analyzers and is reported as a com-
onent of the complete blood count. Red cell distribution
idth is typically elevated in conditions of ineffective red cell
roduction (such as iron deficiency, B12 or folate deficiency,
nd hemoglobinopathies), increased red cell destruction
such as hemolysis), or after blood transfusion. Conceivably,
DW may represent an integrative measure of multiple
athologic processes in heart failure (e.g., nutritional defi-
iencies, renal dysfunction, hepatic congestion, inflamma-
ory stress), explaining its association with clinical outcomes.
lthough not previously correlated with cardiovascular out-
omes, elevation of RDW has been associated with other
isease processes, including liver disease, malnutrition, occult
olon cancer, and neoplastic metastases to marrow (11,12).
A variety of mechanisms have been proposed for the
ssociation between anemia and outcomes in heart failure,
ncluding inflammatory stress, nutritional deficiencies, in-
dequate production of erythropoietin, and the impact of
omorbidities (13). Any or all of these mechanisms could
lso impact RDW. It is possible that the relationship of
hese variables and outcome is more directly reflected
hrough impact on RDW than on hemoglobin. However, in
2oth the CHARM program and the Duke Databank,
DW was only modestly correlated with serum hemoglo-
in, and remained an independent predictor of outcome
fter adjusting for hemoglobin.
Red cell distribution width also may be related to other
nown markers of prognosis in heart failure, such as inflam-
atory cytokines. Inflammatory cytokines have been shown to
e predictors of prognosis in heart failure, and also may
mpact bone marrow function and iron metabolism (14,15).
roinflammatory cytokines have been found to inhibit
rythropoietin-induced erythrocyte maturation, which is
eflected in part by an increase in RDW (16). Future studies
hat carefully evaluate RDW in the context of more com-
lete evaluation of iron metabolism and markers of inflam-
ation in heart failure patients may provide further insight
nto the mechanisms of the interaction between the hema-
ologic and cardiovascular systems.
tudy limitations. Chi-square statistics reflect the statis-
ical significance of relationships, but do not provide a
ormal evaluation of the contribution of a variable to
xplained variance, and as such are not a formal measure
f predictive validity. We did not focus on model
erformance because the purpose of this analysis was not
o develop a risk model, but rather to explore novel
actors that may be prognostically important and thus
arrant further investigation.
This study is a retrospective review of clinical datasets
ithout a prespecified hypothesis, and as such is subject to
he limitations of this type of analysis. Given the large
umber of potential predictors evaluated and the initial lack
f hypothesis-guided selection of variables, some observed
ssociations in the derivation dataset may be related to
hance alone. However, the high level of statistical signifi-
ance observed for RDW in both the derivation dataset and
eplication dataset minimizes this possibility.
onclusions
e identified elevated RDW as a novel and important
redictor of morbidity and mortality in patients with
hronic heart failure. Red cell distribution width, a largely
verlooked variable available to clinicians for most of their
atients with heart failure, has greater independent associ-
tion with outcome than many other clinical and laboratory
arameters promoted for use in estimating prognosis. This
tudy should prompt further evaluation of the association
etween RDW and outcome in heart failure to improve
nderstanding of pathophysiology and to better risk-stratify
atients with chronic heart failure.
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